The U.S. office-based labs market size was exhibited at USD 11.65 billion in 2023 and is projected to hit around USD 24.10 billion by 2033, growing at a CAGR of 7.54% during the forecast period 2024 to 2033.
Report Coverage | Details |
Market Size in 2024 | USD 12.53 Billion |
Market Size by 2033 | USD 24.10 Billion |
Growth Rate From 2024 to 2033 | CAGR of 7.54% |
Base Year | 2023 |
Forecast Period | 2024-2033 |
Segments Covered | Modality, Services, Specialists |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Key Companies Profiled | Koninklijke Philips N.V., GE Healthcare, Siemens Healthineers AG, Medtronic PLC, Boston Scientific Corporation, Abbott, Cardiovascular Systems, Inc., Envision Healthcare, Surgery Care Associate, Inc (SCA); Surgery Partners, National Cardiovascular Partners, Cardiovascular Collation; TH Medical |
The growing trend of surgical procedures being performed in outpatient settings and the rising incidence of various vascular diseases are among the major factors driving the demand for office-based labs (OBL) in the U.S. Additionally, high patient satisfaction with a focused and dedicated team of doctors is expected to boost the market growth.
The prevalence of these diseases has significantly increased over the past decade and is expected to continue growing at an exponential rate. The U.S. witnessed a growth of 13% in the number of individuals suffering from Peripheral Artery Disease (PAD) in the past decade. PAD increases the risk of stroke and heart attack and often lead to ischemic amputations. Thus, increasing the demand for vascular surgical procedures. Many service providers, such as National Cardiovascular Partners, Envision Healthcare, and Surgery Partners are/ providing office-based surgical solutions and services to patients at an affordable cost.
Furthermore, key manufacturers, such as Philips Healthcare and Siemens Healthineers, have been entering into partnerships with physicians to set up OBLs, equipping laboratories with required devices and providing complete solutions from start to end, which is expected to propel the market growth. The changing reimbursement policies for surgical procedures are boosting the scope of surgical procedures in office-based settings. In 2021, the Centers for Medicare and Medicaid Services proposed new standards for reimbursed procedures conducted in ASCs and broadened the scope of surgical procedures payable when performed in outpatient settings.
This policy change also positively affected peripheral vascular interventions. After changes were made in federal reimbursement policy, peripheral vascular interventions have been categorized under outpatient settings. This is comparatively less expensive than in inpatient settings. As compared to Hospital Outpatient (HO) settings, establishing an OBL is beneficial for physicians in terms of reimbursements. The operating cost of an ambulatory center is higher than that of an OBL due to high patient safety standards and stringent regulatory scenarios. In some states of the U.S., conversion of an ambulatory center requires a certificate of need, which is a time-consuming procedure. This is creating an opportunity for physicians to convert to OBL settings.
Based on modality, the market is categorized into single specialty, multi-specialty, and hybrid labs. The single specialty modality segment dominated the market in 2023 and accounted for a revenue share of 41.77%. Single specialty centers are growing at a significant rate due to their investment-friendly model and importance in specified specialties, such as ophthalmology, urology, plastics, and gastroenterology. Single specialty clinics are more cost-efficient in comparison with multi-specialty hospitals that require many resources to support multiple service lines, leading to an increase in operational costs.
The hybrid labs segment is expected to register the fastest CAGR during the forecast period owing to technological advancements, an increase in reimbursement rates, and a rise in the number of minimally invasive procedures. In addition, improvements in technology, providing high-quality and convenient solutions for patients, are projected to support the growth of this segment. The hybrid lab operates as an OBL for a few days of the week and as an ASC on other days. Thus, hybrid labs increase the volume of procedures & reimbursement for providers and significantly enhance the efficiency and utilization of OBL/ASC.
Based on services, the OBLs market has been categorized into peripheral vascular intervention, endovascular intervention, cardiac, interventional radiology, venous, and others. The peripheral vascular intervention segment dominated the market in 2023 on account of the increased prevalence of PAD, favorable reimbursement, and technological advancements in minimally invasive vascular procedures.
Industry players are trying to strengthen their peripheral intervention product offerings to commercialize the growing opportunities in OBL settings. In March 2021, Cardiovascular Systems, Inc. acquired WavePoint Medical’s line of peripheral support catheters, which are used in peripheral vascular intervention. Under this acquisition agreement, WavePoint Medical would develop a specialty catheter portfolio used in complex percutaneous coronary intervention and chronic total occlusions for Cardiovascular Systems, Inc.
The interventional radiology segment is estimated to register the fastest CAGR over the forecast period. Interventional radiology is beginning to play a vital role in the adoption of value-based healthcare models. Interventional radiology helps diagnose and treat patients using the least invasive techniques that are less expensive, cause minimum pain, and need less recovery time in comparison with traditional surgery. It utilizes image-guided procedures, such as MRI, CT, and ultrasound, to guide minimally invasive procedures to diagnose and treat diseases in every organ system. According to Cardiovascular Disease Management Annual Symposium, around 12% of interventional radiologists performed office-based interventions in the U.S.
Based on specialists, the market has been further classified into vascular surgeons, interventional cardiologists, interventional radiologists, and others. The vascular surgeon segment dominated the market in 2023 owing to the advancements in medical technology, an increase in the demand for specialists, and a shift in preference from hospital settings to OBLs for better & more efficient care.
The interventional radiologist segment is expected to grow at the fastest growth rate during the forecast period on account of the increasing use of minimally invasive image-guided techniques for the diagnosis and treatment of diseases. Advancements in medical technology, increasing preference for better & efficient care, and patient demographics are factors expected to fuel the demand for vascular specialists.
Currently, there is a shortage of physicians for vascular surgery. According to the Society for Vascular Surgery, 100 million people in the U.S. are at risk of vascular disease. The office-based labs are the top preference of vascular surgeons, as performing surgeries at office-based facilities has financial benefits for them, with all the excess margin for surgical procedures going to the surgeon directly & indirectly. Moreover, interventional radiology reduces cost, recovery time, pain, and risk to patients.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. office-based labs market
Modality
Service
Specialist
Chapter 1. Methodology and Scope
1.1. Market Segmentation
1.2. Market Definitions
1.2.1. Modality
1.2.2. Service
1.2.3. Specialist
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.4.1. Information procurement
1.4.2. Purchased Database
1.4.3. Internal Database
1.4.4. Secondary Sources
1.4.5. Primary Research
1.4.6. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.6.1. Commodity Flow Analysis
1.7. List of Secondary Sources
1.8. List of Abbreviations
1.9. Research Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.2.1. Modality
2.2.2. Service
2.2.3. Specialist
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.2. Market Segmentation
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Increasing prevalence of target diseases
3.3.1.2. Preference to minimally invasive procedures
3.3.2. Market Restraint Analysis
3.3.2.1. High risk option for severe cases
3.3.2.2. Lack of technical training for the MIS procedure
3.3.3. Industry Opportunity Analysis
3.3.3.1. Approval of endovascular procedures in office-based labs
3.3.3.2. Flexibility for physicians to convert to OBLs
3.4. Regulatory Framework & Reimbursement Scenario
3.4.1. Regulatory Framework
3.4.2. Reimbursement Scenario
3.5. Industry Analysis Tools
3.5.1. Porter's Five Forces Analysis
3.5.2. PESTLE Analysis
Chapter 4. U.S. Office-Based Labs Market: Modality Analysis
4.1. U.S. Office-based Labs (OBLs): Modality Market Share Analysis, 2024 & 2033
4.2. Segment Dashboard
4.3. U.S. Office-based Labs (OBLs) Market, by Modality, 2021 - 2033
4.4. Market Size and Forecasts and Trend Analysis, 2021 - 2033 for the Modality
4.4.1. Single Specialty Labs
4.4.1.1. Single specialty labs market, 2021 - 2033 (USD Million)
4.4.2. Multi-Specialty Labs
4.4.2.1. Multi-specialty labs market, 2021 - 2033 (USD Million)
4.4.3. Hybrid Labs
4.4.3.1. Hybrid labs market, 2021 - 2033 (USD Million)
Chapter 5. U.S. Office-Based Labs Market: Service Analysis
5.1. U.S. Office-based Labs (OBLs): Service Market Share Analysis, 2024 & 2033
5.2. Segment Dashboard
5.3. U.S. Office-based Labs (OBLs) Market, by Modality, 2021 - 2033
5.4. Market Size and Forecasts and Trend Analysis, 2021 - 2033 for the Service
5.4.1. Peripheral Vascular Intervention
5.4.1.1. Peripheral vascular intervention market, 2021 - 2033 (USD Million)
5.4.2. Cardiac
5.4.2.1. Cardiac market, 2021 - 2033 (USD Million)
5.4.3. Interventional Radiology
5.4.3.1. Interventional radiology market, 2021 - 2033 (USD Million)
5.4.4. Venous
5.4.4.1. Venous market, 2021 - 2033 (USD Million)
5.4.5. Endovascular Interventions
5.4.5.1. Endovascular interventions market, 2021 - 2033 (USD Million)
5.4.6. Others
5.4.6.1. Others market, 2021 - 2033 (USD Million)
Chapter 6. U.S. Office-Based Labs Market: Specialist Analysis
6.1. U.S. Office-based Labs (OBLs): Specialist Market Share Analysis, 2024 & 2033
6.2. Segment Dashboard
6.3. U.S. Office-based Labs (OBLs) Market, by Modality, 2021 - 2033
6.4. Market Size and Forecasts and Trend Analysis, 2021 - 2033 for the Specialist
6.4.1. Vascular Surgeons
6.4.1.1. Vascular surgeons market, 2021 - 2033 (USD Million)
6.4.2. Interventional Cardiologists
6.4.2.1. Interventional cardiologists market, 2021 - 2033 (USD Million)
6.4.3. Interventional Radiologists
6.4.3.1. Interventional radiologists market, 2021 - 2033 (USD Million)
6.4.4. Other Specialists
6.4.4.1. Other specialists market, 2021 - 2033 (USD Million)
Chapter 7. U.S. Office-Based Labs Market: Regional Analysis
7.1. U.S. Office-Based Labs (OBLs) Market, 2021 - 2033 (USD Million)
7.2. U.S Office-Based Labs (OBLs) Market: Top 5 States
7.2.1. Penetration Analysis: Top 5 states 2024
7.3. Pricing Analysis
7.3.1. Average cost of major procedures performed in office-based labs
7.3.2. Average cost of major devices used in office-based labs
7.3.3. Average cost of setting up an office-based labs
Chapter 8. Competitive Analysis
8.1. Company Profiles
8.1.1. Suppliers
8.1.1.1. Koninklijke Philips N.V
8.1.1.1.1. Overview
8.1.1.1.2. Financial Performance
8.1.1.1.3. Product Benchmarking
8.1.1.1.4. Strategic Initiatives
8.1.1.2. GE Healthcare
8.1.1.2.1. Overview
8.1.1.2.2. Financial Performance
8.1.1.2.3. Product Benchmarking
8.1.1.2.4. Strategic Initiatives
8.1.1.3. Siemens Healthineers AG
8.1.1.3.1. Overview
8.1.1.3.2. Financial Performance
8.1.1.3.3. Product Benchmarking
8.1.1.3.4. Strategic Initiatives
8.1.1.4. Medtronic PLC
8.1.1.4.1. Overview
8.1.1.4.2. Financial Performance
8.1.1.4.3. Product Benchmarking
8.1.1.4.4. Strategic Initiatives
8.1.1.5. Boston Scientific Corporation
8.1.1.5.1. Overview
8.1.1.5.2. Financial Performance
8.1.1.5.3. Product Benchmarking
8.1.1.5.4. Strategic Initiatives
8.1.1.6. Abbott
8.1.1.6.1. Overview
8.1.1.6.2. Financial Performance
8.1.1.6.3. Product Benchmarking
8.1.1.6.4. Strategic Initiatives
8.1.1.7. Cardiovascular Systems, Inc.
8.1.1.7.1. Overview
8.1.1.7.2. Financial Performance
8.1.1.7.3. Product Benchmarking
8.1.1.7.4. Strategic Initiatives
8.1.2. Service Providers
8.1.2.1. Envision Healthcare Corporation
8.1.2.1.1. Overview
8.1.2.1.2. Financial Performance
8.1.2.1.3. Service Benchmarking
8.1.2.1.4. Strategic Initiatives
8.1.2.2. Surgical Care Affiliates (SCA)
8.1.2.2.1. Overview
8.1.2.2.2. Financial Performance
8.1.2.2.3. Service Benchmarking
8.1.2.2.4. Strategic Initiatives
8.1.2.3. Fresenius Medical Car
8.1.2.3.1. Overview
8.1.2.3.2. Financial Performance
8.1.2.3.3. Service Benchmarking
8.1.2.3.4. Strategic Initiatives
8.1.2.4. Cardiovascular Coalition
8.1.2.4.1. Overview
8.1.2.4.2. Financial Performance
8.1.2.4.3. Service Benchmarking
8.1.2.4.4. Strategic Initiatives
8.1.2.5. Surgery Partners
8.1.2.5.1. Overview
8.1.2.5.2. Financial Performance
8.1.2.5.3. Service Benchmarking
8.1.2.5.4. Strategic Initiatives
8.1.2.6. TH Medical
8.1.2.6.1. Overview
8.1.2.6.2. Financial Performance
8.1.2.6.3. Service Benchmarking
8.1.2.6.4. Strategic Initiatives
8.2. Company Categorization: Suppliers
8.3. Company Categorization: Service Providers
8.4. Company Market Position Analysis: Suppliers
8.5. Company Market Position Analysis: Service Providers
8.6. Company Market Position Analysis: Imaging Devices Manufacturer
8.7. Company Market Position Analysis: Vascular Intervention Devices
8.8. Strategy Mapping
Chapter 9. KOL Comments & Recommendations